Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

OBJECTIVES:

Primary

• Determine the hematologic and nonhematologic toxicities of decitabine in combination with tretinoin in patients with myelodysplastic syndromes. (Phase I)
• Determine the maximum tolerated dose of tretinoin when administered with decitabine in these patients. (Phase I)
• Determine the clinical remission rate (complete and partial remission) in patients treated with this regimen. (Phase II)
• Determine the rate of hematologic improvement in these patients. (Phase II)

Secondary

• Determine the efficacy of this regimen, in terms of improved bone marrow function, by monitoring frequency of transfusion, bleeding, and infection, as well as changes in bone marrow morphology and cytogenetics in these patients.
• Assess differentiation by morphology and flow cytometry and apoptosis by flow cytometry in patients treated with this regimen.
• Determine if gene expression changes in these patients are induced by this regimen.
• Determine the efficacy of this regimen, in terms of inducing demethylation of specific genes, in these patients.
• Correlate clinical response with gene expression, demethylation of specific genes, and flow cytometric indicators of differentiation and apoptosis.

OUTLINE: This is a phase I, dose-escalation study of tretinoin followed by a phase II, open-label study.

• Phase I: Patients receive decitabine IV over 1 hour once daily on days 1-5 followed by oral tretinoin twice daily on days 10-19. Treatment repeats every 28 days for a minimum of 4 courses in the absence of disease progression or excessive toxicity. Patients who achieve a partial or complete response after completing 6 courses of treatment may receive 4 additional courses up to a total of 10 courses. Patients with stable disease or hematologic improvement are removed from study.

Cohorts of 3-6 patients receive escalating doses of tretinoin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity attributable to tretinoin at any dose level during course 1. A total of 6 patients are treated at the MTD.

• Phase II: Patients receive decitabine as in phase I and tretinoin at the MTD. Patients undergo blood and bone marrow collection periodically during study for correlative demethylation and gene profiling studies and for evidence of differentiation and apoptosis. Samples are examined by flow cytometry, cytogenetics, histochemistry, and array-based whole genome methylation analysis.

After completion of study treatment, patients are followed at 30 days.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

• Histologically confirmed myelodysplastic syndromes (MDS)
• International Prognostic scoring system (IPSS) score ≥ 0.5, including the following:

• Untreated or treated intermediate-1 risk disease
• Intermediate-2 risk disease
• High-risk disease
• No treatment-related MDS
• Ineligible for transplantation
• No decitabine-refractory disease defined as disease progression after discontinuation of therapy

• If previously treated with decitabine, must have responded to therapy (hematologic improvement or better per International Working Group Response Criteria)

PATIENT CHARACTERISTICS:

• Karnofsky performance status 60-100%
• Bilirubin ≤ 2.5 mg/dL
• AST and ALT ≤ 2 times upper limit of normal (ULN)
• Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other medical condition that, in the opinion of the treating physician, would preclude patient compliance or put patient at excessive risk of treatment-related toxicity
• No other malignancy that would likely require systemic chemotherapy within 4 months after starting study treatment
• No allergy to parabens, vitamin A, or retinoids

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Prior azacytidine allowed
• More than 4 weeks since prior cytotoxic chemotherapy or radiotherapy
• More than 4 weeks since prior experimental therapy
• Concurrent myeloid growth factors allowed only in the setting of febrile neutropenia according to established guidelines for use